Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Syros Pharmaceuticals Inc    SYRS

SYROS PHARMACEUTICALS INC

(SYRS)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
7.52(c) 7.63(c) 7.59(c) 7.57(c) 7.4(c) Last
174 798 126 908 136 026 98 160 93 570 Volume
-14.06% +1.46% -0.52% -0.26% -2.25% Change
More quotes
Financials (USD)
Sales 2019 1,76 M
EBIT 2019 -75,8 M
Net income 2019 -73,4 M
Debt 2019 -
Yield 2019 -
Sales 2020 1,27 M
EBIT 2020 -86,1 M
Net income 2020 -84,1 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -4,13x
P/E ratio 2020 -3,98x
Capi. / Sales2019 179x
Capi. / Sales2020 246x
Capitalization 314 M
More Financials
Company
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is... 
Sector
Pharmaceuticals
Calendar
08/07Earnings Release
More about the company
Surperformance© ratings of Syros Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on SYROS PHARMACEUTICALS INC
06/12SYROS PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Submiss..
AQ
06/12SYROS PHARMACEUTICALS : Announces Appointment of Alice T. Shaw to its Board of D..
BU
06/12SYROS PHARMACEUTICALS : to Present at JMP Securities Life Sciences Conference
BU
05/08SYROS PHARMACEUTICALS : New Publication in Cancer Research Highlights Discovery ..
AQ
05/07SYROS PHARMACEUTICALS : New Publication in Cancer Research Highlights Discovery ..
BU
05/01SYROS PHARMACEUTICALS : Reports First Quarter 2019 Financial Results and Highlig..
BU
05/01SYROS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
04/24SYROS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and..
AQ
04/24SYROS PHARMACEUTICALS : to Report First Quarter 2019 Financial Results on Wednes..
BU
04/17SYROS PHARMACEUTICALS : to Host Key Opinion Leader Symposium on CDK7 Inhibition ..
BU
More news
Sector news : Biopharmaceuticals
05:45aJOHNSON & JOHNSON : Faces Key Test in Defense Against Talc-Safety Lawsuits
DJ
07/19CELGENE : Says FDA Approves Otezla for Oral Ulcers in Behcet's Disease
DJ
07/19ALLERGAN : Form 8.3 -
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19JOHNSON & JOHNSON : J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in M..
DJ
More sector news : Biopharmaceuticals
Chart SYROS PHARMACEUTICALS INC
Duration : Period :
Syros Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYROS PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 15,83  $
Last Close Price 7,40  $
Spread / Highest target 224%
Spread / Average Target 114%
Spread / Lowest Target 35,1%
EPS Revisions
Managers
NameTitle
Nancy A. Simonian President, Chief Executive Officer & Director
Peter Wirth Chairman
Joseph J. Ferra Chief Financial Officer
Eric R. Olson Chief Scientific Officer
David A. Roth Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SYROS PHARMACEUTICALS INC32.85%314
CSL LIMITED21.21%71 775
BIOGEN-23.15%44 842
ALEXION PHARMACEUTICALS26.60%27 088
GRIFOLS24.80%19 360
SAMSUNG BIOLOGICS CO LTD--.--%16 204